Drug intelligence / Profile preview

sanzihuangshi

Development stage: Unknown
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

Sanzihuangshi (Sanzi-huangshi pill) is an arsenic-containing traditional Chinese medicine that has been used for decades as a potential treatment for myelodysplastic syndromes (MDS). Its mechanism of action is not fully elucidated, but it is believed to exert therapeutic effects through the pharmacological activity of arsenic compounds. The efficacy and safety profile of Sanzihuangshi in MDS remains under investigation, with clinical trials ongoing to establish its benefit as an adjuvant therapy in relatively low-risk MDS patients[1][2][3].

Brand names: sanzihuangshi pill
Other names: sanzi-huangshi pill三子黄石丸

Beyond the preview

Go deeper on sanzihuangshi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sanzihuangshi.

Explore the full profile